Prosit Sole Biotechnology

company

About

Prosit Sole is a biotechnology company focused on developing a new class of drugs.

  • 1 - 10

Details

Last Funding Type
Series B
Industries
Biotechnology,Pharmaceutical
Founded date
Apr 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

Deyi Sunshine Biotechnology (Beijing) Co., Ltd. was established in April 2013 in Zhongguancun Biomedical Park, Haidian District, Beijing. In March 2014, it established a subsidiary Deyang Biotechnology in Gu'an Emerging Industry Demonstration Zone, Langfang City, Hebei Province. (Gu'an) limited liability company. Deyi Sunshine is a biotechnology company focused on developing a new class of drugs. The company has a world-leading innovative biopharmaceutical research and development platform. Based on the analysis of the industry and relying on the unique core technology-Sunshine Protein Optimization Platform, the company has successfully developed Pegelan (a kind of innovation for treating chronic norovirus infection in patients with immune deficiency). Orphan drug), Sporphene (an innovative orphan drug for minimally invasive repair of articular cartilage injury), Perox (an innovative orphan drug for the treatment of stubborn gout with visible crystals) and Defenfen (for the treatment of lupus erythematosus) A class of innovative drugs for renal failure and uremia) and many other world-leading research results. The research varieties all have independent intellectual property rights of the active ingredients of the drug. It is expected that the future listing will not only bring good news to the patients with rare diseases in the world, but also hope to expand into other indications and become a major innovative product. All the staff of the company adhere to the tenet of “Deze human beings, benefit the country and the people, and the healthy people”. We have the entrepreneurial spirit of “independent innovation and courage to open up” and make unremitting efforts to build China's first-class bio-pharmaceutical company!

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Prosit Sole Biotechnology has raised a total of — in funding over 2 rounds. Their latest funding was raised on Feb 7, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 7, 2021 Series B 1 Longmen Capital Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Prosit Sole Biotechnology is funded by 1 investors. Longmen Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Longmen Capital Yes Series B